4 Stocks Improving Performance Of The Health Care Sector

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 10 points (-0.1%) at 15,618 as of Friday, Aug. 2, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,354 issues advancing vs. 1,554 declining with 118 unchanged.

The Health Care sector currently sits up 0.2% versus the S&P 500, which is down 0.1%. Top gainers within the sector include Biogen Idec ( BIIB), up 2.8%, Smith & Nephew ( SNN), up 2.6%, Grifols ( GRFS), up 1.3% and Pfizer ( PFE), up 0.6%. On the negative front, top decliners within the sector include Sirona Dental Systems ( SIRO), down 5.3%, Regeneron Pharmaceuticals ( REGN), down 2.3%, Vertex Pharmaceuticals ( VRTX), down 2.0%, Celgene Corporation ( CELG), down 2.0% and Baxter International ( BAX), down 1.9%.

TheStreet would like to highlight 4 stocks pushing the sector higher today:

4. Shire ( SHPG) is one of the companies pushing the Health Care sector higher today. As of noon trading, Shire is up $0.96 (0.9%) to $111.95 on light volume. Thus far, 112,814 shares of Shire exchanged hands as compared to its average daily volume of 482,500 shares. The stock has ranged in price between $111.17-$112.39 after having opened the day at $111.35 as compared to the previous trading day's close of $110.99.

Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). Shire has a market cap of $20.2 billion and is part of the drugs industry. Shares are up 18.6% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate Shire a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Shire Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Novartis ( NVS) is up $0.73 (1.0%) to $72.71 on average volume. Thus far, 712,890 shares of Novartis exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $72.35-$72.94 after having opened the day at $72.55 as compared to the previous trading day's close of $71.98.

Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $175.2 billion and is part of the drugs industry. Shares are up 13.7% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Novartis a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Novartis Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, GlaxoSmithKline ( GSK) is up $0.33 (0.6%) to $52.10 on heavy volume. Thus far, 1.8 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $51.93-$52.46 after having opened the day at $52.13 as compared to the previous trading day's close of $51.77.

GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $125.3 billion and is part of the drugs industry. Shares are up 17.2% year to date as of the close of trading on Thursday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Eli Lilly and Company ( LLY) is up $0.30 (0.6%) to $53.80 on light volume. Thus far, 1.2 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5.4 million shares. The stock has ranged in price between $53.22-$53.84 after having opened the day at $53.47 as compared to the previous trading day's close of $53.50.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $59.8 billion and is part of the drugs industry. Shares are up 8.5% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Eli Lilly and Company a buy, 2 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, compelling growth in net income, impressive record of earnings per share growth and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Eli Lilly and Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?